Amprolium hydrochloride pharma-grade API is a quaternary thiamine analogue with high aqueous solubility; this property influences dissolution but also makes wet-granulation endpoint control critical. The API is released against a current veterinary pharmacopoeial monograph with assay 98.0–101.0% on dried basis, loss on drying ≤1.0%, and sulfated ash ≤0.1%. The crystalline fraction is milled to a particle-size distribution of D₁₀ ≤20 µm, D₅₀ 45–75 µm, and D₉₀ ≤120 µm for direct compression. A starting formulation for a 250 mg amprolium HCl tablet at 600 mg total mass contains 41.7% w/w API, 34.5% w/w microcrystalline cellulose PH102, 20.0% w/w spray-dried lactose monohydrate, 2.5% w/w croscarmellose sodium, 1.0% w/w magnesium stearate, and 0.3% w/w colloidal silicon dioxide. Dry blending is performed in a 300 L bin blender at 12 rpm for 15 min; lubricant is added in a separate blending step of 3 min at 12 rpm to limit shear-induced agglomeration. Compression on a 10-station rotary tablet press with 10 mm round flat-faced bevel-edge tooling is run with precompression 2–3 kN and main compression 8–12 kN, producing tablets with hardness 70–90 N, friability <0.6% per USP <1216>, and disintegration time <15 min in 0.1 N HCl at 37 °C. Dissolution testing per USP <711> apparatus II with 900 mL of pH 1.2 simulated gastric fluid at 50 rpm typically shows Q ≥ 80% at 30 min; published data for this exact formulation is limited, so pharmaceutical development batches are required to qualify incoming API particle-size distribution. For hard gelatin capsules, the milled blend is filled on a dosator-type capsule machine with size 1 capsules at 25,000–40,000 capsules/h; fill weight is adjusted to 300–500 mg depending on dose. Powder bridging is observed when blend bulk density falls below 0.42 g/mL, so precompression or roller compaction is introduced.

What Limits Blend Uniformity in Low-Dose Amprolium Premix Dilution?

Low-dose amprolium feed premixing combines the API into Type A medicated articles at 20–25% w/w for subsequent dilution into finished feed. The finished feed concentration in broiler chickens is typically 60–120 g per tonne, equivalent to 60–120 mg/kg. This low inclusion rate makes segregation and poor carrier adhesion the dominant causes of out-of-specification assay results. The first dilution step combines amprolium HCl with a carrier such as calcium carbonate or ground corn cobs and 2% w/w mineral oil; the mixture is passed through a 500 µm screen before loading into a ribbon mixer. A 10% w/w intermediate premix is then diluted to 0.5% w/w in the same mixer using baffled shafts at 25–30 rpm for 10–15 min. Blend uniformity is tested by collecting 10 thief samples at predefined points and assaying amprolium content; acceptance is a relative standard deviation ≤5.0% and mean assay 90.0–110.0% of label claim. FDA 21 CFR 558.55 authorizes amprolium Type A medicated articles for broiler chickens, replacement chickens, and turkeys under specified use levels. Segregation in finished feed can be reduced by maintaining carrier bulk density within 10% of the API bulk density and by using vacuum coating systems. Batch-to-batch variation is monitored by periodic particle-size analysis of the Type A article; drift in D₅₀ above 250 µm correlates with poor distribution in pelleted feeds.

A drinking-water granule line handling 20% w/w amprolium HCl uses wet granulation in a top-spray fluid-bed dryer. The dry blend consists of 20.0% w/w amprolium HCl, 60.0% w/w dextrose monohydrate, 10.0% w/w citric acid, 7.0% w/w sodium bicarbonate, and 3.0% w/w povidone K30 as binder. Granulation fluid is purified water sprayed at 30–40 g/min per kg dry charge with inlet air temperature 60–65 °C and product temperature 35–40 °C. The resulting granule is classified to 18–60 mesh; fines below 60 mesh are recycled into the next granulation batch. Final moisture is dried to 1.5–2.5% w/w and measured by Karl Fischer titration; moisture above 3.0% w/w causes caking during storage at 40 °C/75% RH. The granule is packed in foil-lined heat-sealed sachets at 50 g, 100 g, and 500 g. For prevention, the granule is added to drinking water to yield 60 mg/L; for treatment, the concentration is raised to 120 mg/L for 3–5 days. The final solution pH is between 4.0 and 5.5; at pH above 6.0, amprolium hydrochloride degradation in the presence of chlorinated drinking water is observed as a slow drop in assay after 24 h. Turbidity or insoluble particles in the drinking water line are controlled by specifying water hardness below 150 mg/L CaCO₃ and by preventing simultaneous dosing with alkaline veterinary additives. Published stability data for this specific sachet configuration is limited.

When a 9.6% w/v Oral Drench Is Buffered Below pH 4.0

For oral drench manufacture, amprolium hydrochloride is formulated as a 9.6% w/v oral solution for calves, sheep, and goats under 21 CFR 520.100. The formulation vehicle is purified water with 0.1% w/w sodium benzoate and 0.05% w/w disodium edetate; buffering with citric acid/sodium citrate maintains pH 4.0–4.5. Below pH 4.0, the solution can become corrosive to aluminum transfer lines used in automatic dosing systems; above pH 5.5, physical stability limitations arise with precipitation of trace metal complexes. Batch manufacturing uses a 5000 L stainless steel mixing vessel with bottom-mounted propeller agitation at 200–300 rpm, and the API is added through a vacuum transfer wand after the buffer salts are fully dissolved. The solution is filtered through 0.45 µm nylon media prior to filling into high-density polyethylene jugs with induction-sealed caps. Filling line speed is typically 80–120 bottles/min for 950 mL containers. In case of pH drift above 5.0, rework is not permitted because the degradation product profile may include thiamine-like byproducts, and the batch is rejected. For oral drench administration, dosing is weight-banded under veterinary direction; the product is not intended for feed mixing.

Roller Compaction Parameters for High-Load Tablets

High-load amprolium HCl tablet formulations above 60% w/w API often fail direct-compression flow tests because the API bulk density can be as low as 0.35 g/mL and the angle of repose exceeds 40°. Roller compaction is introduced at 10–15 kN/cm roll force with a roll gap of 1.5–2.5 mm and roll speed of 4–8 rpm on an Alexanderwerk WP120 or equivalent. Ribbons are milled through a 1.0 mm Conidur screen to produce granules with D₅₀ 250–400 µm and bulk density 0.55–0.65 g/mL. The granules are then mixed with 20.0% w/w microcrystalline cellulose, 3.0% w/w crospovidone, 1.0% w/w magnesium stearate, and 0.5% w/w colloidal silicon dioxide before tabletting. The process solves sticking problems at main compression forces above 12 kN by reducing unprocessed API surface contact with punches. The equivalence of the granulated intermediate is confirmed by dissolution profile comparison using f₂ similarity factor; f₂ >50 is required against the direct-compression reference batch per FDA SUPAC guidance. Tablets produced from roller-compacted granules show hardness 80–100 N, friability <0.4%, and disintegration time <10 min in 0.1 N HCl.

Injectable Solution Manufacture Is Governed by Terminal Sterilization and USP <788>

Injectable-grade amprolium HCl solution is manufactured in an ISO 8 cleanroom with terminal sterilization at 121 °C for 15 min. The bulk solution contains 9.6% w/v amprolium HCl in Water for Injection and is buffered with 0.1 M citrate buffer to pH 4.0–4.5. The fill volume is 100 mL or 250 mL in amber Type I glass vials with bromobutyl rubber stoppers. Terminal sterilization requires prefiltration through 0.22 µm PVDF and nitrogen sparging to reduce oxygen headspace. Particulate matter is controlled per USP <788>: for containers above 100 mL, the acceptance limit is ≤25 particles ≥10 µm per mL and ≤3 particles ≥25 µm per mL. Sterility is tested per USP <71>. The injectable route is not approved in every regulatory jurisdiction; published pharmacokinetic data for parenteral amprolium in target species is limited. The solution should not be mixed with calcium-containing infusion fluids because citrate complexation can produce visible precipitation. In regions where injectable compounding is authorized under veterinary prescription, the product is assigned a short beyond-use date of 24 h at room temperature after first puncture per USP <797>.